Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?

dc.contributor.authorMartin-Nuñez, Gracia M
dc.contributor.authorCornejo-Pareja, Isabel
dc.contributor.authorClemente-Postigo, Mercedes
dc.contributor.authorTinahones, Francisco J
dc.date.accessioned2025-01-07T17:20:53Z
dc.date.available2025-01-07T17:20:53Z
dc.date.issued2021-06-17
dc.description.abstractHelicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. Although the majority of infected individuals remain asymptomatic, this bacterium colonizes the gastric mucosa causing the development of various clinical conditions as peptic ulcers, chronic gastritis and gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas, but complications are not limited to gastric ones. Extradigestive pathologies, including metabolic disturbances such as diabetes, obesity and nonalcoholic fatty liver disease, have also been associated with H. pylori infection. However, the underlying mechanisms connecting H. pylori with extragastric metabolic diseases needs to be clarified. Notably, the latest studies on the topic have confirmed that H. pylori infection modulates gut microbiota in humans. Damage in the gut bacterial community (dysbiosis) has been widely related to metabolic dysregulation by affecting adiposity, host energy balance, carbohydrate metabolism, and hormonal modulation, among others. Taking into account that Type 2 diabetic patients are more prone to be H. pylori positive, gut microbiota emerges as putative key factor responsible for this interaction. In this regard, the therapy of choice for H. pylori eradication, based on proton pump inhibitor combined with two or more antibiotics, also alters gut microbiota composition, but consequences on metabolic health of the patients has been scarcely explored. Recent studies from our group showed that, despite decreasing gut bacterial diversity, conventional H. pylori eradication therapy is related to positive changes in glucose and lipid profiles. The mechanistic insights explaining these effects should also be addressed in future research. This review will deal with the role of gut microbiota as the linking factor between H. pylori infection and metabolic diseases, and discussed the impact that gut bacterial modulation by H. pylori eradication treatment can also have in host's metabolism. For this purpose, new evidence from the latest human studies published in more recent years will be analyzed.
dc.identifier.doi10.3389/fendo.2021.639856
dc.identifier.issn1664-2392
dc.identifier.pmcPMC8247771
dc.identifier.pmid34220702
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8247771/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fendo.2021.639856/pdf
dc.identifier.urihttps://hdl.handle.net/10668/28332
dc.journal.titleFrontiers in endocrinology
dc.journal.titleabbreviationFront Endocrinol (Lausanne)
dc.language.isoen
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number639856
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHelicobacter pylori
dc.subjectdiabetes
dc.subjecteradication therapy for Helicobacter pylori
dc.subjectgut microbiota
dc.subjectmetabolic diseases
dc.subjectmetabolism
dc.subject.meshAnimals
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshCarbohydrate Metabolism
dc.subject.meshDysbiosis
dc.subject.meshGastric Mucosa
dc.subject.meshGastrointestinal Microbiome
dc.subject.meshGlucose
dc.subject.meshHelicobacter Infections
dc.subject.meshHelicobacter pylori
dc.subject.meshHumans
dc.subject.meshMetabolic Diseases
dc.subject.meshPeptic Ulcer
dc.subject.meshProtein Transport
dc.subject.meshSequence Analysis, DNA
dc.titleGut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8247771.pdf
Size:
568.12 KB
Format:
Adobe Portable Document Format